Form 4: ProMIS Neurosciences Director Josh Mandel-Brehm Granted 20,000 Stock Options

ProMIS Neurosciences Inc. Director Josh Mandel-Brehm was granted 20,000 stock options with an exercise price of $0.50, vesting by June 12, 2026.

Summary

• Josh Mandel-Brehm, a Director of ProMIS Neurosciences Inc. (PMN), was granted 20,000 stock options.
• The options have an exercise price of $0.50 per common share.
• The grant date for these options was June 12, 2025.
• The options will vest in full on the earlier of the first anniversary of the grant date (June 12, 2026) or June 12, 2026, contingent on his continued service on the Board.
• The options expire on June 12, 2035.

Sentiment

Score: 6

Explanation: The document reports a routine grant of stock options to a director, which is a positive for aligning management incentives with shareholder interests, but it does not contain information that would significantly alter the company's financial outlook or operational status.

Positives

• The grant of 20,000 stock options to Director Josh Mandel-Brehm aligns his interests with shareholder value creation.
• The options have a long expiration date of June 12, 2035, providing a significant window for potential value realization.

Future Outlook

NA

Industry Context

This Form 4 filing is a standard disclosure of an insider transaction, specifically the grant of stock options to a director, which is a common form of executive and director compensation in the biotechnology and pharmaceutical industries to incentivize long-term performance and align interests with shareholders.

Comparison to Industry Standards

• The grant of stock options to directors is a common practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology, as a means of non-cash compensation and to align director incentives with shareholder value creation. The specific terms (exercise price, vesting schedule, expiration) would typically be benchmarked against peer companies of similar size and stage within the biotech industry, though this document does not provide such comparative data.

Related Party Transactions

• The grant of 20,000 stock options to Josh Mandel-Brehm, a Director of ProMIS Neurosciences Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholders, potentially incentivizing long-term value creation.

Next Steps

• The options granted to Josh Mandel-Brehm are scheduled to vest in full on the earlier of the first anniversary of the grant date (June 12, 2026) or June 12, 2026, subject to his continued service on the Board.

Key Dates

Keywords

ProMIS Neurosciences, PMN, stock options, insider transaction, Form 4, director compensation, Josh Mandel-Brehm